Through his Cedar clinics he has offered thousands of people relief through the use of ketamine in courses of therapy for depression.ĭr. Robison is a thought leader in the world of therapeutic psychedelics.
Reid Robison, an MD and MBA who is the founder of Cedar Psychiatry and Cedar Clinical Research in Salt Lake City, Utah.
Suicidal ideation can lead to suicide, depression can lead to suicide, adult eating disorders are a leading cause of death from mental illness.Īnswering the question “Who is treating people today?” led Conforti to Dr. There are literally millions of people who have been diagnosed with a mental health condition and that issue has proven refractory to the current range of drug and other treatment. Here is the thing, depending on which numbers you use, servicing the mental health sector with new protocols for treatment resistant illnesses could be a $5- to $25-billion a year business, or more. This is a meat and potatoes approach to an emerging sector in which it is easy to buy into smoke and mirrors. “In what jurisdiction? And how can we invest?” “Who is treating people today?” Conforti asked. After a very successful career in what he described as “ frontier investing”, Conforti had a very clear idea of what he was looking for in the sector. “In early 2019 we were travelling and attending conferences,” said Conforti. Novamind’s CEO, Yaron Conforti, recognized that a suite of psychoactive drugs were on the track towards legalization for therapeutic use for mental health problems ranging from depression, anorexia and suicidal ideation. The coming legalization and regulation of “psychedelics” is just such an opportunity and just listed Canadian company, Novamind (NM.C) and ( OTCPK:NVMDF) is positioned to participate and prosper. Investors are not often offered an opportunity to participate in a brand new, multi-billion dollar, industry.
0 kommentar(er)
